智翔金泰：2025年度净亏损5.36亿元

Core Viewpoint - Zhixiang Jintai (688443.SH) reported significant revenue growth for the fiscal year 2025, driven by the expansion of its commercialized product sales and licensing agreements, despite still posting a net loss [1] Financial Performance - The company achieved total operating revenue of 231 million yuan, representing a year-on-year increase of 666.65% [1] - The net profit attributable to the parent company was a loss of 536 million yuan, which is a 32.74% reduction in losses compared to the previous year [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was a loss of 579 million yuan, reflecting a 27.99% decrease in losses year-on-year [1] Revenue Drivers - The increase in operating revenue is primarily attributed to the market expansion of the first commercialized product, Saliqi monoclonal antibody injection (Jinlixi®), which saw steady growth in sales revenue compared to the same period last year [1] - Significant licensing income from the GR1803 injection's licensing and commercialization agreement positively impacted the company's net profit for the period [1]